<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">sechenov</journal-id><journal-title-group><journal-title xml:lang="en">Sechenov Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Сеченовский вестник</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2218-7332</issn><issn pub-type="epub">2658-3348</issn><publisher><publisher-name>Сеченовский Университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47093/22187332.2019.4.21-30</article-id><article-id custom-type="elpub" pub-id-type="custom">sechenov-179</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PATHOLOGICAL PHYSIOLOGY</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПАТОЛОГИЧЕСКАЯ ФИЗИОЛОГИЯ</subject></subj-group></article-categories><title-group><article-title>Long-term use of dipeptyl peptidase-4 inhibitors suppresses systemic oxidative stress in rats with type 2 diabetes</article-title><trans-title-group xml:lang="ru"><trans-title>Длительное применение ингибиторов дипептилпептидазы-4 подавляет системный окислительный стресс у крыс с диабетом 2 типа</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5794-9263</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Болевич</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Bolevich</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Болевич Стефани Сергеевна,  ассистент кафедры патофизиологии</p><p>ул. Трубецкая, д. 8, стр. 2, г. Москва, 119991Тел.: +7 (903) 787-44-66 </p></bio><bio xml:lang="en"><p>Stefani S. Bolevich, Assistant Professor at the Pathophysiology Department</p><p>8/2 Trubetskaya st., Moscow, 119991Tel.: +7 (903) 787-44-66 </p></bio><email xlink:type="simple">alistra555@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0151-9114</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Литвицкий</surname><given-names>П. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Litvitsky</surname><given-names>P. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Литвицкий Петр Францевич, д-р мед. наук, профессор, чл.-кор. РАН, заведующий кафедрой патофизиологии</p><p>г. Москва</p></bio><bio xml:lang="en"><p>Petеr F. Litvitsky, Doctor of Medical Science, Professor,  Corresponding member of RAS, Head of the Pathophysiology Department</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0071-8376</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковлевич</surname><given-names>В.</given-names></name><name name-style="western" xml:lang="en"><surname>Jakovljevic</surname><given-names>V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Яковлевич Владимир, д-р мед. наук, профессор, декан факультета медицинских наук</p><p>г. Крагуевац</p></bio><bio xml:lang="en"><p>Vladimir Jakovljevic, MD, Professor, Dean of the Faculty of Medical Sciences</p><p>Kragujevac</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1574-477X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Болевич</surname><given-names>С. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Bolevich</surname><given-names>S. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Болевич Сергей Бранкович, д-р мед. наук, профессор, заведующий кафедрой патологии человека</p><p>г. Москва</p></bio><bio xml:lang="en"><p>Sergey B. Bolevich, Doctor of Medical Science, Professor, Head of the Human Pathology Department</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Крагуевацкий Университет</institution><country>Чехословакия</country></aff><aff xml:lang="en"><institution>University of Kragujevac</institution><country>Czechoslovakia</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2019</year></pub-date><volume>10</volume><issue>4</issue><fpage>21</fpage><lpage>30</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Bolevich S.S., Litvitsky P.F., Jakovljevic V., Bolevich S.B., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Болевич С.С., Литвицкий П.Ф., Яковлевич В., Болевич С.Б.</copyright-holder><copyright-holder xml:lang="en">Bolevich S.S., Litvitsky P.F., Jakovljevic V., Bolevich S.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sechenovmedj.com/jour/article/view/179">https://www.sechenovmedj.com/jour/article/view/179</self-uri><abstract><p>Induction of oxidative stress is one of the main mechanisms responsible for the development of micro- and macrovascular angiopathy in patients with type 2 diabetes mellitus (DM-2).</p><sec><title>Aim</title><p>Aim. To evaluate the inﬂuence of long-term treatment with inhibitors of dipeptidyl peptidase-4 (DPP-4) on the characteristics of oxidative stress and the state of antioxidant defense system in rats with induced DM 2.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We divided 60 Wistar albino rats into 5 groups: group 1 (control) – normal animals; groups 2–5 rats with DM 2, induced by streptozotocin: group 2 – without treatment with DPP 4; group 3 – rats, treated with saxagliptin (0.45 mg/kg); group 4 – rats, treated with sitagliptin for 3 weeks (0.6 mg/kg); group 5 – rats, treated with vildagliptin (9 mg/kg). At the end of the experimental phase we determined the level of superoxide anion radical (O2-), hydrogen peroxide (H2O2), nitrite (NO2-), reduced glutathione, as well as the activity of catalase and superoxide dismutase (SOD) in the blood of rats using a diode array spectrophotometer.</p></sec><sec><title>Results</title><p>Results. Induction of DM-2 in experimental animals led to a signiﬁcant increase of reactive oxygen species (ROS): superoxide radical and hydrogen peroxide and to decrease in NO2-, reduced glutathione, catalase and SOD activity. Comparing groups 3–5 with group 2, treatment with DPP-4 inhibitors reduced excessive generation of superoxide radical (O2-) and hydrogen peroxide (H2O2) (especially signiﬁcant in the group with vildagliptin) and increased the activity of catalase and superoxide dismutase (especially signiﬁcant in the group with v sitagliptin) but the normal values, received in group 1, were not reached. Treatment with all DPP-4 inhibitors brought the level of nitrite (NO2-) up to normal, comparable with group 1.</p></sec><sec><title>Conclusions</title><p>Conclusions. DPP-4 inhibitors suppress systemic oxidative stress in rats with induced DM 2 via reduction of prooxidative molecules production and activation of antioxidant defensive system.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Одним из основных механизмов формирования микро- и макрососудистых ангиопатий у пациентов с сахарным диабетом 2-го типа (СД 2) служит индукция окислительного стресса.</p><sec><title>Цель</title><p>Цель. Изучить влияние трехнедельного применения ингибиторов дипептидилпептидазы-4 (ДПП-4) на показатели окислительного стресса и состояние системы антиоксидантной защиты у крыс с индуцированным СД 2. Материалы и методы. 60 крыс линии Wistar albino разделены на 5 групп: группа 1 (контроль) – интактные животные. У крыс в группах 2–5 с помощью стрептозотоцина моделирован СД 2. В следующие 3 нед группа 2 не получала лечения, в группе 3 вводили саксаглиптин (0,45 мг/кг), в группе 4 – ситаглиптин (0,6 мг/кг), в группе 5 – вилдаглиптин (9 мг/кг). По завершении эксперимента животных анестезировали и брали кровь для определения уровня супероксидного анион-радикала (O2-), перекиси водорода (Н2O2), нитрита (NO2-), восстановленного глутатиона, а также активность каталазы и супероксиддисмутазы (СОД) с помощью диодноматричного спектрофотометра.</p></sec><sec><title>Результаты</title><p>Результаты. Индуцирование СД 2 вызывало статистически значимое увеличение уровня активных форм кислорода: O2- и Н2O2 ; снижение уровня: NO2- , восстановленного глутатиона, активности каталазы и СОД. Введение ингибиторов ДПП-4 в группах 3–5 приводило к подавлению избыточной генерации O2- и Н2O2 (эффект наиболее выражен у вилдаглиптина) и повышению активности каталазы и СОД (эффект наиболее выражен у ситаглиптина) по сравнению с группой 2. Однако эти показатели не достигали значений, регистрируемых в группе 1. Введение всех трех ДПП-4 приводило к достижению цифр, сопоставимых с контролем по уровню NO2- . По уровню малонового диальдегида различий между группами не установлено.</p></sec><sec><title>Выводы</title><p>Выводы. Ингибиторы ДПП-4 подавляют системный окислительный стресс у крыс с индуцированным СД 2 за счет торможения генерации прооксидантов и повышения активности антиоксидантной защиты.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>диабет 2-го типа</kwd><kwd>саксаглиптин</kwd><kwd>ситаглиптин</kwd><kwd>вилдаглиптин</kwd><kwd>окислительный стресс</kwd><kwd>антиоксидантная защита</kwd></kwd-group><kwd-group xml:lang="en"><kwd>type 2 diabetes mellitus</kwd><kwd>saxagliptine</kwd><kwd>sitagliptine</kwd><kwd>vildagliptine</kwd><kwd>oxidative stress</kwd><kwd>antioxidant defensive system</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И. Сахарный диабет типа 2: от теории к практике. Москва: МИА, 2016; 576c. ISBN 978-5-9986-0248-1.</mixed-citation><mixed-citation xml:lang="en">Dedov I.I. Saharnyj diabet tipa 2. Ot teorii k praktike. / Type 2 diabetes mellitus: from theory to practice. Moscow: MIA, 2016; 576p. [in Russian]. ISBN 978-5-9986-0248-1.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017; 20 (1): 13–41.</mixed-citation><mixed-citation xml:lang="en">Dedov I.I., Shestakova M.V., Vikulova O.K. Epidemiologiia sakharnogo diabeta v Rossiiskoi Federatsii: kliniko-statisticheskii analiz po dannym Federal'nogo registra sakharnogo diabeta. | Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes Mellitus. 2017; 20 (1): 13–41. [in Russian]. DOI: 10.14341/DM8664.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018; 130 (1): 72-82. DOI: 10.1080/00325481.2018.1394152. PMID: 29039237.</mixed-citation><mixed-citation xml:lang="en">Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018; 130 (1): 72-82. DOI: 10.1080/00325481.2018.1394152. PMID: 29039237.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В. Осложнения сахарного диабета. Лечение и профилактика. Москва: МИА, 2017; 744 с. ISBN 978-5-9986-0300-6.</mixed-citation><mixed-citation xml:lang="en">Dedov I.I., Shestakova M.V. Oslozhnenija saharnogo diabeta. Lechenie i profilaktika. / Complications of diabetes. Treatment and prevention. Moscow: MIA, 2017; 744. [in Russian]. ISBN 978-5-9986-0300-6.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Румянцева С.А., Силина Е.В., Орлова А.С. и др. Гипергликемия и свободнорадикальный дисбаланс как прогностические маркеры острого нарушения мозгового кровообращения. Анналы клинической и экспериментальной неврологии. 2012; 6 (4): 26-9.</mixed-citation><mixed-citation xml:lang="en">Rumyantceva S.A., Silina E.V., Orlova A.S. et al. Giperglikemiia i svobodnoradikal'nyi disbalans kak prognosticheskie markery ostrogo narusheniia mozgovogo krovoobrashcheniia. / Hyperglycemia and free radical imbalance as prognostic factors of stroke. Annaly klinicheskoj i eksperimental'noj nevrologii. 2012; 6 (4): 26-9. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sani NF, Belani LK, Sin CP et al. Effect of the combination of gelam honey and ginger on oxidative stress and metabolic profile in streptozotocin-induced diabetic Sprague-Dawley rats. Biomed Res Int. 2014: 160695. DOI: 10.1155/2014/160695. PMID: 24822178.</mixed-citation><mixed-citation xml:lang="en">Sani NF, Belani LK, Sin CP et al. Effect of the combination of gelam honey and ginger on oxidative stress and metabolic profile in streptozotocin-induced diabetic Sprague-Dawley rats. Biomed Res Int. 2014: 160695. DOI: 10.1155/2014/160695. PMID: 24822178.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab. 2011; 15: 298–308. DOI: 10.4103/2230-8210.85583. PMID: 22029001</mixed-citation><mixed-citation xml:lang="en">Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab. 2011; 15: 298–308. DOI: 10.4103/2230-8210.85583. PMID: 22029001</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tatosian DA, Guo Y, Schaeffer AK, et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther. 2013 Dec; 4 (2): 431-42. DOI: 10.1007/s13300-013-0045-8. PMID: 24163113</mixed-citation><mixed-citation xml:lang="en">Tatosian DA, Guo Y, Schaeffer AK, et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther. 2013 Dec; 4 (2): 431-42. DOI: 10.1007/s13300-013-0045-8. PMID: 24163113</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jakovljevic V, Milic P, Bradic J, et al. Standardized Aronia melanocarpa Extract as Novel Supplement against Metabolic Syndrome: A Rat Model. Int J Mol Sci. 2018 Dec 20; 20 (1): 6. DOI: 10.3390/ijms20010006. PMID: 30577476.</mixed-citation><mixed-citation xml:lang="en">Jakovljevic V, Milic P, Bradic J, et al. Standardized Aronia melanocarpa Extract as Novel Supplement against Metabolic Syndrome: A Rat Model. Int J Mol Sci. 2018 Dec 20; 20 (1): 6. DOI: 10.3390/ijms20010006. PMID: 30577476.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hulman A., Vistisen D., Glümer C. et al. Glucose patterns during an oral glucose tolerance test and associations with future diabetes, cardiovascular disease and all-cause mortality rate. Diabetologia. 2018. Vol. 61 (1): 101–7. DOI: 10.1007/s00125-017-4468-z. PMID: 28983719.</mixed-citation><mixed-citation xml:lang="en">Hulman A., Vistisen D., Glümer C. et al. Glucose patterns during an oral glucose tolerance test and associations with future diabetes, cardiovascular disease and all-cause mortality rate. Diabetologia. 2018. Vol. 61 (1): 101–7. DOI: 10.1007/s00125-017-4468-z. PMID: 28983719.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng Y., Ley S., Hu F. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018. Vol. 14 (2): 88–98. DOI: 10.1038/nrendo.2017.151. PMID: 29219149.</mixed-citation><mixed-citation xml:lang="en">Zheng Y., Ley S., Hu F. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018. Vol. 14 (2): 88–98. DOI: 10.1038/nrendo.2017.151. PMID: 29219149.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rehman K, Akash MSH. Mechanism of Generation of Oxidative Stress and Pathophysiology of Type 2 Diabetes Mellitus How Are They Interlinked? J Cell Biochem. 2017; 118 (11) :3577-85. DOI:10.1002/jcb.26097</mixed-citation><mixed-citation xml:lang="en">Rehman K, Akash MSH. Mechanism of Generation of Oxidative Stress and Pathophysiology of Type 2 Diabetes Mellitus How Are They Interlinked? J Cell Biochem. 2017; 118 (11) :3577-85. DOI:10.1002/jcb.26097</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Breitzig M, Bhimineni C, Lockey R, Kolliputi N. 4-Hydroxy-2-nonenal: a critical target in oxidative stress? Am J Physiol Cell Physiol. 2016 Oct 1; 311 (4): C537-C543. DOI: 10.1152/ajpcell.00101.2016</mixed-citation><mixed-citation xml:lang="en">Breitzig M, Bhimineni C, Lockey R, Kolliputi N. 4-Hydroxy-2-nonenal: a critical target in oxidative stress? Am J Physiol Cell Physiol. 2016 Oct 1; 311 (4): C537-C543. DOI: 10.1152/ajpcell.00101.2016</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nowotny K, Jung T, Höhn A, et al. Advanced glycation end productsand oxidative stress in type 2 diabetes mellitus, Biomolecules. 2015; 5 (1): 194-222. DOI: 10.3390/biom5010194.</mixed-citation><mixed-citation xml:lang="en">Nowotny K, Jung T, Höhn A, et al. Advanced glycation end productsand oxidative stress in type 2 diabetes mellitus, Biomolecules. 2015; 5 (1): 194-222. DOI: 10.3390/biom5010194.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Pеrez-Matute P, Zulet MA, Martínez JA. Reactive species and diabetes: counteracting oxidative stress to improve health. Curr Opin Pharmacol. 2009; 9 (6): 771-9. DOI: 10.1016/j.coph.2009.08.005.</mixed-citation><mixed-citation xml:lang="en">Pеrez-Matute P, Zulet MA, Martínez JA. Reactive species and diabetes: counteracting oxidative stress to improve health. Curr Opin Pharmacol. 2009; 9 (6): 771-9. DOI: 10.1016/j.coph.2009.08.005.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Murakami K, Kondo T, Ohtsuka Y. et al. Impairment of glutathione metabolism in erythrocytes from patients with diabetes mellitus. Metabolism. 1989; 38 (8): 753-8. DOI: 10.1016/0026-0495(89)90061-9. PMID: 2569661</mixed-citation><mixed-citation xml:lang="en">Murakami K, Kondo T, Ohtsuka Y. et al. Impairment of glutathione metabolism in erythrocytes from patients with diabetes mellitus. Metabolism. 1989; 38 (8): 753-8. DOI: 10.1016/0026-0495(89)90061-9. PMID: 2569661</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kottenberg E, Thielmann M, Kleinbongard P, et al. Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation. ActaAnaesthesiol Scand. 2014; 58 (4): 453-62. DOI: 10.1111/aas.12278. PMID: 24548338.</mixed-citation><mixed-citation xml:lang="en">Kottenberg E, Thielmann M, Kleinbongard P, et al. Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation. ActaAnaesthesiol Scand. 2014; 58 (4): 453-62. DOI: 10.1111/aas.12278. PMID: 24548338.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tatosian DA, Guo Y, Schaeffer AK, et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Therapy. 2013; 4 (2): 431-42. DOI:10.1007/s13300-013-0045-8</mixed-citation><mixed-citation xml:lang="en">Tatosian DA, Guo Y, Schaeffer AK, et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Therapy. 2013; 4 (2): 431-42. DOI:10.1007/s13300-013-0045-8</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Sherif IO, Al-Shaalan NH. Vildagliptin Attenuates Hepatic Ischemia/Reperfusion Injury via the TLR4/NF-κB Signaling Pathway. Oxid Med Cell Longev. 2018: 3509091. DOI:10.1155/2018/3509091. PMID: 30405876.</mixed-citation><mixed-citation xml:lang="en">Sherif IO, Al-Shaalan NH. Vildagliptin Attenuates Hepatic Ischemia/Reperfusion Injury via the TLR4/NF-κB Signaling Pathway. Oxid Med Cell Longev. 2018: 3509091. DOI:10.1155/2018/3509091. PMID: 30405876.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">El-Kashef DH, Serrya MS. Sitagliptin ameliorates thioacetamide-induced acuteliver injury via modulating TLR4/NF-KB signaling pathway in mice. Life Sci. 2019; 228: 266-273. DOI:10.1016/j.lfs.2019.05.019.</mixed-citation><mixed-citation xml:lang="en">El-Kashef DH, Serrya MS. Sitagliptin ameliorates thioacetamide-induced acuteliver injury via modulating TLR4/NF-KB signaling pathway in mice. Life Sci. 2019; 228: 266-273. DOI:10.1016/j.lfs.2019.05.019.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sangle G., Patil M., Deshmukh N. et al. Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. European journal of clinical pharmacology. 2018. Vol. 74 (5): 561–569. DOI: 10.1007/s00228-018-2433-5.</mixed-citation><mixed-citation xml:lang="en">Sangle G., Patil M., Deshmukh N. et al. Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. European journal of clinical pharmacology. 2018. Vol. 74 (5): 561–569. DOI: 10.1007/s00228-018-2433-5.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Trocha M, Krzystek-Korpacka M, Merwid-Ląd A, et al. Sitagliptin-Dependent Differences in the Intensity of Oxidative Stress in Rat Livers Subjected to Ischemia and Reperfusion. Oxid Med Cell Longev. 2019 Oct 31: 2738605. DOI:2019:2738605. PMID: 31781329</mixed-citation><mixed-citation xml:lang="en">Trocha M, Krzystek-Korpacka M, Merwid-Ląd A, et al. Sitagliptin-Dependent Differences in the Intensity of Oxidative Stress in Rat Livers Subjected to Ischemia and Reperfusion. Oxid Med Cell Longev. 2019 Oct 31: 2738605. DOI:2019:2738605. PMID: 31781329</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Refaat R, Sakr A, Salama M, El Sarha A. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats. Drug Dev Res. 2016; 77 (6): 300-9. DOI:10.1002/ddr.21324.</mixed-citation><mixed-citation xml:lang="en">Refaat R, Sakr A, Salama M, El Sarha A. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats. Drug Dev Res. 2016; 77 (6) :300-9. DOI:10.1002/ddr.21324.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Helal MG, Zaki MMAF, Said E. Nephroprotective effect of saxagliptin againstgentamicin-induced nephrotoxicity, emphasis on anti-oxidant, anti-inflammatoryand anti-apoptic effects. Life Sci. 2018; 208 : 64-71. DOI:10.1016/j.lfs.2018.07.021.</mixed-citation><mixed-citation xml:lang="en">Helal MG, Zaki MMAF, Said E. Nephroprotective effect of saxagliptin againstgentamicin-induced nephrotoxicity, emphasis on anti-oxidant, anti-inflammatoryand anti-apoptic effects. Life Sci. 2018; 208 : 64-71. DOI:10.1016/j.lfs.2018.07.021.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
